156 related articles for article (PubMed ID: 22961216)
1. Injection site reaction after subcutaneous administration of bortezomib in Japanese patients with multiple myeloma.
Kamimura T; Miyamoto T; Takashima S; Yokota N; Chong Y; Ito Y; Akashi K
Int J Hematol; 2012 Oct; 96(4):525-7. PubMed ID: 22961216
[No Abstract] [Full Text] [Related]
2. Subcutaneous bortezomib: a step towards optimised drug use.
Mateos MV
Lancet Oncol; 2011 May; 12(5):410-1. PubMed ID: 21507716
[No Abstract] [Full Text] [Related]
3. An acceptable incidence of infusion site reactions after subcutaneous bortezomib administration in the upper arm in Japanese patients with multiple myeloma.
Ohgiya D; Tsuchiya T; Suyama T; Watanabe S; Numata H; Tsuboi K; Sasao T
Acta Haematol; 2015; 133(1):29-30. PubMed ID: 24993672
[No Abstract] [Full Text] [Related]
4. Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study.
Moreau P; Pylypenko H; Grosicki S; Karamanesht I; Leleu X; Rekhtman G; Masliak Z; Robak P; Esseltine DL; Feng H; Deraedt W; van de Velde H; Arnulf B
Haematologica; 2015 May; 100(5):e207-10. PubMed ID: 25596270
[No Abstract] [Full Text] [Related]
5. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.
Moreau P; Pylypenko H; Grosicki S; Karamanesht I; Leleu X; Grishunina M; Rekhtman G; Masliak Z; Robak T; Shubina A; Arnulf B; Kropff M; Cavet J; Esseltine DL; Feng H; Girgis S; van de Velde H; Deraedt W; Harousseau JL
Lancet Oncol; 2011 May; 12(5):431-40. PubMed ID: 21507715
[TBL] [Abstract][Full Text] [Related]
6. Cutaneous lesion induced by a subcutaneous administration of bortezomib.
Obeid KM; Ferrara R; Sharma M
Clin Lymphoma Myeloma Leuk; 2012 Aug; 12(4):284-6. PubMed ID: 22633164
[No Abstract] [Full Text] [Related]
7. Bortezomib-associated peripheral neuropathy requiring medical treatment is decreased by administering the medication by subcutaneous injection in Korean multiple myeloma patients.
Koh Y; Lee SY; Kim I; Kwon JH; Yoon SS; Park S; Chung MH; Suh SY; Kim KS; Kim HS
Cancer Chemother Pharmacol; 2014 Sep; 74(3):653-7. PubMed ID: 25096796
[TBL] [Abstract][Full Text] [Related]
8. Lupus tumidus induced by bortezomib not requiring discontinuation of the drug.
Aguayo-Leiva I; Vano-Galvan S; Carrillo-Gijon R; Jaén-Olasolo P
J Eur Acad Dermatol Venereol; 2010 Nov; 24(11):1363-4. PubMed ID: 20337821
[No Abstract] [Full Text] [Related]
9. Bortezomib-related diffuse alveolar hemorrhage.
Wirk B
J Clin Oncol; 2012 Dec; 30(36):e379-81. PubMed ID: 23150703
[No Abstract] [Full Text] [Related]
10. [Effective control of skin reaction by air sandwich technique in a patient with IgE-κ myeloma treated with subcutaneous bortezomib injection].
Honda Y; Inoue J; Shingaki S; Miyazaki K; Abe Y; Sekine E; Iki S; Tsukada N; Suzuki K
Rinsho Ketsueki; 2014 May; 55(5):570-2. PubMed ID: 24881924
[TBL] [Abstract][Full Text] [Related]
11. Adenovirus-associated hemorrhagic cystitis in a patient with plasma cell myeloma treated with bortezomib.
Yokose N; Hirakawa T; Inokuchi K
Leuk Res; 2009 Aug; 33(8):e106. PubMed ID: 19285724
[No Abstract] [Full Text] [Related]
12. Feasibility and efficacy of administration of bortezomib-containing regimens to patients over the age of 70 years.
Parrish C; Cromack J; Feyler S; Ashcroft J; Owen R; Cook G
Br J Haematol; 2011 Apr; 153(2):273-5. PubMed ID: 21275974
[No Abstract] [Full Text] [Related]
13. Higher incidence of injection site reactions after subcutaneous bortezomib administration on the thigh compared with the abdomen.
Kamimura T; Miyamoto T; Yokota N; Takashima S; Chong Y; Ito Y; Akashi K
Eur J Haematol; 2013 Feb; 90(2):157-61. PubMed ID: 23240903
[TBL] [Abstract][Full Text] [Related]
14. Bortezomib-induced skin eruption.
Sanchez-Politta S; Favet L; Kerl K; Dietrich PY; Piguet V
Dermatology; 2008; 216(2):156-8. PubMed ID: 18216478
[TBL] [Abstract][Full Text] [Related]
15. Bortezomib administration with severe hyperbilirubinemia caused by hepatic plasma cell infiltration: a case report.
Wilson N; Surati M; Walker BF; Kaufman JL; Harvey RD
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):159-61. PubMed ID: 23084405
[No Abstract] [Full Text] [Related]
16. Delayed flare reaction of draining vein due to subcutaneous bortezomib more likely to occur at the inner thigh.
Imataki O; Ota S; Aoyama M; Kubo H; Hamasaki Y; Kida J; Oku M; Uemura M; Ohue Y
Int J Hematol; 2015 Jan; 101(1):99-101. PubMed ID: 25286749
[No Abstract] [Full Text] [Related]
17. Bortezomib-induced perivascular dermatitis in a patient with multiple myeloma.
Ozkurt ZN; Sucak GT; Aki SZ; Yağci M; Erdem O
Cutan Ocul Toxicol; 2009; 28(3):141-3. PubMed ID: 19548772
[TBL] [Abstract][Full Text] [Related]
18. Intravenous bortezomib for multiple myeloma that has progressed after subcutaneous bortezomib therapy.
Kuroda J; Mizutani S; Shimura Y; Maegawa S; Nagoshi H; Chinen Y; Tatekawa S; Tsukamoto T; Mizuno Y; Yamamoto-Sugitani M; Kobayashi T; Matsumoto Y; Horiike S; Taniwaki M
Ann Hematol; 2015 Apr; 94(4):687-9. PubMed ID: 25209844
[No Abstract] [Full Text] [Related]
19. [Bortezomib-associated acute congestive heart failure in a patient with multiple myeloma].
Aota Y; Gotoh A; Hanyu N; Honma T; Morisaki M; Yokoyama T; Kitagawa N; Komatsu N
Rinsho Ketsueki; 2015 Jan; 56(1):44-7. PubMed ID: 25745969
[TBL] [Abstract][Full Text] [Related]
20. [Clinical development of a proteasome inhibitor, bortezomib, for the treatment of myeloma and lymphoma].
Tobinai K
Rinsho Ketsueki; 2007 Jun; 48(6):451-7. PubMed ID: 17633092
[No Abstract] [Full Text] [Related]
[Next] [New Search]
